All News

Officials with the FDA have approved fast-acting insulin aspart (Fiasp, Novo Nordisk) for the treatment of adults with diabetes.

The Improving Transparency and Accuracy in Medicare Part D Spending Act seeks to halt direct and indirect remuneration fees on Part D claims without any defect, impropriety, or fraud.

The Improving Transparency and Accuracy in Medicare Part D Spending Act would end direct and indirect remuneration fees.

Top news of the day from across the health care landscape.

Inhibiting neuroligin-3 in mice delayed the proliferation of high-grade glioma.

The 3-in-1 antibody protected laboratory monkeys from SHIV.

Prescribing beta blockers after a heart attack may be unnecessary.

Drinking at least 1 cup of coffee per day could reduce the risk of all-cause mortality by 51%.

Top news of the day from across the healthcare landscape.

A look at the top stories in pharmacy last week.

Guanfacine (Intuniv) for attention-deficit hyperactivity disorder (ADHD) shows marked clinical improvement in global functioning.

FDA advisory committee votes the data was inconclusive on ataluren (translarna), a first-in-class oral treatment for Duchenne muscular dystrophy.

While the FAERS dashboard now offers stakeholders many more ways of searching for and organizing data on adverse events reported to the FDA for many drug and biologic products, there remain limitations to the data.

Pertussis or whooping cough is a highly contagious respiratory disease that can be very serious and even fatal for infants younger than 1.

FDA expands approved indications for ibrutinib in August 2017.

A look at unintentional causes of injury death in the United States and medication safety.

Eliminating retroactive pharmacy payment reductions — or post point-of-sale pharmacy "DIR fees" — in Medicare Part D would save the federal government $3.4 billion over 10 years, according to a Wakely Consulting Group study released today by the National Community Pharmacists Association.

Abemaciclib treats adults with hormone receptor-positive, human epidemical growth factor receptor-negative advanced or metastatic breast cancer that progressed after endocrine therapy.

Verzenio can be administered as a stand-alone treatment to patients previously treated with endocrine therapy and chemotherapy.

Officials with the FDA have approved abemaciclib (Verzenio, Eli Lilly), for the treatment of adults with certain advanced or metastatic breast cancer.

The agreement requires Amgen to pay royalties to AbbVie for sales of the biosimilar, according to a press release.

Reports from an investment bank suggest Amazon is looking to collaborate with a PBM.

CVS to limit opioid prescriptions to 7 days for certain conditions.

Higher-income individuals living in low-income areas had lower cardiovascular risks than those with lower incomes.

Promotion of healthy lifestyle changes are crucial among HIV-positive patients cured of hepatitis C.

Top news of the day from across the health care landscape.

Agreement clears path to launch of Humira biosimilar.

AbbVie grants commercialization rights to Amjevita.

Top news of the day from across the healthcare landscape.

The award goes to the organization that has done the most to advance patient care and the practice of specialty pharmacy.